Preserved peritoneal function by short-term two-day peritoneal rest in hemodialysis combination therapy patients

Ueda, Atsushi; Nagai, Kei; Yamagata, Kunihiro

doi:10.1007/s10047-020-01215-7

Cited by 6 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peritoneal rest has been recommended to prevent, slow down or even reverse peritoneal fibrosis [ 46 , 56 ]. Peritoneal rest is an attempt to stop the continuous exposure of the peritoneum to dialysate fluid which can cause MMT in peritoneal mesothelial cells.…”

Section: Peritoneal Rest In Pd-associated Peritoneal Fibrosismentioning

confidence: 99%

Current Insights into Cellular Determinants of Peritoneal Fibrosis in Peritoneal Dialysis: A Narrative Review

Suryantoro

Wungu

Sutanto

et al. 2023

JCM

View full text Add to dashboard Cite

Peritoneal fibrosis is the final process of progressive changes in the peritoneal membrane due to chronic inflammation and infection. It is one of the main causes of discontinuation of peritoneal dialysis (PD), apart from peritonitis and cardiovascular complications. Over time, morphological changes occur in the peritoneal membranes of patients who use PD. Of those are mesothelial-to-mesenchymal transition (MMT), neoangiogenesis, sub-mesothelial fibrosis, and hyalinizing vasculopathy. Several key molecules are involved in the complex pathophysiology of peritoneal fibrosis, including advanced glycosylation end products (AGEs), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF). This narrative review will first discuss the physiology of the peritoneum and PD. Next, the multifaceted pathophysiology of peritoneal fibrosis, including the effects of hyperglycemia and diabetes mellitus on the peritoneal membrane, and the promising biomarkers of peritoneal fibrosis will be reviewed. Finally, the current and future management of peritoneal fibrosis will be discussed, including the potential benefits of new-generation glucose-lowering medications to prevent or slow down the progression of peritoneal fibrosis.

show abstract

Section: Peritoneal Rest In Pd-associated Peritoneal Fibrosismentioning

confidence: 99%